Quantitative determination of EPA and DHA in fish oil capsules for cardiovascular disease therapy in Indonesia by GC-MS

Lorensia, Amelia and Budiono, Ryanto and Suryadinata, Rivan Virlando and Tiarasari, Navy (2021) Quantitative determination of EPA and DHA in fish oil capsules for cardiovascular disease therapy in Indonesia by GC-MS. Journal of Public Health Research, 10 (2).

[thumbnail of Amelia Lorensia_Quantitative determination of EPA and DHA_2159-Article Text-10391-2-10-20210414.pdf] PDF
Amelia Lorensia_Quantitative determination of EPA and DHA_2159-Article Text-10391-2-10-20210414.pdf

Download (1MB)
Official URL / DOI: https://www.jphres.org/index.php/jphres/article/vi...

Abstract

Background: The consumption of EPA (Eicosapentaenoic acid), and DHA (docosahexaenoic acid), from fish oil, in the long run, has been observed to have a positive impact on patients with coronary heart disease. Fish oil products, with so much EPA and DHA content are available, and have very variable prices. Therefore, as a therapy to be used for long-term treatment, the cost factor is to be considered. Design and methods: This study analyzed the content of EPA and DHA, using GC-MS. The sample to be analyzed was the fish oil that has the lowest price (Product A1), and that of the highest (Product A2). Furthermore, the macroscopic analysis was performed, by observing the physical form including organoleptic and qualitative tests, by reading the fragments identified by EPA and DHA. Results: Clinical trials were conducted on patients (about people), with risk factors and dyslipidemia. Product A1 EPA at tR= 15.574 min (relative%= 88.49%, similarity= 95%), and DHA at tR= 21.714 min (relative%= 88.92%, similarity= 93%). Product A2 showed EPA at tR= 28.719 min (relative%= 22.58%, similarity= 89%), and DHA at tR= 32.327 min (relative%= 22.87%, similarity= 90%), which meant that both DHA contents, in accordance with their labels. products were confirmed to reduce total cholesterol in 0.000, p= 0.000), with no significant difference in effectiveness (p=0.652). Conclusion: The results showed both the A1 and A2 products, had the EPA and DHA in accordance with their respective labels. However, A2 product having a percentage relatively higher than that of the A1 brand, both are equally very effective.

Item Type: Article
Uncontrolled Keywords: EPA, DHA, fish oil, cardiovascular disease, GC-MS
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Pharmacy > Department of Pharmacy
Depositing User: Ester Sri W. 196039
Date Deposited: 19 Apr 2021 07:15
Last Modified: 19 Apr 2021 07:15
URI: http://repository.ubaya.ac.id/id/eprint/39325

Actions (login required)

View Item View Item